Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays.

Li T, Maus MK, Desai SJ, Beckett LA, Stephens C, Huang E, Hsiang J, Zeger G, Danenberg KD, Astrow SH, Gandara DR.

J Thorac Oncol. 2014 Jan;9(1):18-25. doi: 10.1097/JTO.0000000000000030.

2.

KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.

Maus MK, Grimminger PP, Mack PC, Astrow SH, Stephens C, Zeger G, Hsiang J, Brabender J, Friedrich M, Alakus H, Hölscher AH, Lara P, Danenberg KD, Lenz HJ, Gandara DR.

Lung Cancer. 2014 Feb;83(2):163-7. doi: 10.1016/j.lungcan.2013.11.010. Epub 2013 Nov 21.

PMID:
24331409
3.

Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy.

Maus MK, Mack PC, Astrow SH, Stephens CL, Zeger GD, Grimminger PP, Hsiang JH, Huang E, Li T, Lara PN, Danenberg KD, Gandara DR.

J Thorac Oncol. 2013 May;8(5):582-6. doi: 10.1097/JTO.0b013e318287c3c5.

4.

Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib).

Wilson PM, Yang D, Azuma M, Shi MM, Danenberg KD, Lebwohl D, Sherrod A, Ladner RD, Zhang W, Danenberg PV, Trarbach T, Folprecht G, Meinhardt G, Lenz HJ.

Pharmacogenomics J. 2013 Oct;13(5):410-6. doi: 10.1038/tpj.2012.23. Epub 2012 Jun 5.

PMID:
22664478
5.

Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy.

Pohl A, El-Khoueiry A, Yang D, Zhang W, Lurje G, Ning Y, Winder T, Hu-Lieskoven S, Iqbal S, Danenberg KD, Kahn M, Teo JL, Shriki J, Stebbing J, Lenz HJ.

Pharmacogenomics J. 2013 Apr;13(2):173-80. doi: 10.1038/tpj.2011.61. Epub 2012 Jan 10.

6.

S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma.

Leichman LP, Goldman BH, Bohanes PO, Lenz HJ, Thomas CR, Billingsley KG, Corless CL, Iqbal S, Gold PJ, Benedetti JK, Danenberg KD, Blanke CD.

J Clin Oncol. 2011 Dec 1;29(34):4555-60. doi: 10.1200/JCO.2011.36.7490. Epub 2011 Oct 24.

7.

TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials.

Grimminger PP, Shi M, Barrett C, Lebwohl D, Danenberg KD, Brabender J, Vigen CL, Danenberg PV, Winder T, Lenz HJ.

Pharmacogenomics J. 2012 Oct;12(5):404-11. doi: 10.1038/tpj.2011.29. Epub 2011 Jul 26.

PMID:
21788964
8.

Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer.

Iqbal S, Goldman B, Fenoglio-Preiser CM, Lenz HJ, Zhang W, Danenberg KD, Shibata SI, Blanke CD.

Ann Oncol. 2011 Dec;22(12):2610-5. doi: 10.1093/annonc/mdr021. Epub 2011 Mar 17.

9.

A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance.

Henderson PT, Li T, He M, Zhang H, Malfatti M, Gandara D, Grimminger PP, Danenberg KD, Beckett L, de Vere White RW, Turteltaub KW, Pan CX.

Int J Cancer. 2011 Sep 15;129(6):1425-34. doi: 10.1002/ijc.25814. Epub 2011 Mar 4.

10.

Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study).

Zhang W, Azuma M, Lurje G, Gordon MA, Yang D, Pohl A, Ning Y, Bohanes P, Gerger A, Winder T, Hollywood E, Danenberg KD, Saltz L, Lenz HJ.

Anticancer Res. 2010 Oct;30(10):4209-17.

PMID:
21036743
11.

Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer.

Gandara DR, Grimminger P, Mack PC, Lara PN Jr, Li T, Danenberg PV, Danenberg KD.

J Thorac Oncol. 2010 Dec;5(12):1933-8. doi: 10.1097/JTO.0b013e3181fd418d.

12.

MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.

Hoffmann AC, Wild P, Leicht C, Bertz S, Danenberg KD, Danenberg PV, Stöhr R, Stöckle M, Lehmann J, Schuler M, Hartmann A.

Neoplasia. 2010 Aug;12(8):628-36.

13.

The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes.

Mori R, Dorff TB, Xiong S, Tarabolous CJ, Ye W, Groshen S, Danenberg KD, Danenberg PV, Pinski JK.

Prostate. 2010 Nov 1;70(15):1692-700. doi: 10.1002/pros.21204.

PMID:
20564320
14.

Ornithine decarboxylase mRNA expression in curatively resected non-small-cell lung cancer.

Grimminger PP, Schneider PM, Metzger R, Vallböhmer D, Danenberg KD, Danenberg PV, Hölscher AH, Brabender J.

Clin Lung Cancer. 2010 Mar 1;11(2):114-9. doi: 10.3816/CLC.2010.n.015.

PMID:
20199977
15.

The prognostic role of Bcl-2 mRNA expression in curatively resected non-small cell lung cancer (NSCLC).

Grimminger PP, Schneider PM, Metzger R, Vallböhmer D, Danenberg KD, Danenberg PV, Hölscher AH, Brabender J.

Lung Cancer. 2010 Oct;70(1):82-7. doi: 10.1016/j.lungcan.2009.12.013. Epub 2010 Jan 12.

PMID:
20064672
16.

A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy.

Wilson PM, El-Khoueiry A, Iqbal S, Fazzone W, LaBonte MJ, Groshen S, Yang D, Danenberg KD, Cole S, Kornacki M, Ladner RD, Lenz HJ.

Cancer Chemother Pharmacol. 2010 Apr;65(5):979-88. doi: 10.1007/s00280-009-1236-x.

PMID:
20062993
17.

Epidermal growth factor receptor (EGFR) mRNA levels and protein expression levels in primary colorectal cancer and corresponding liver metastases.

Kuramochi H, Hayashi K, Nakajima G, Kamikozuru H, Yamamoto M, Danenberg KD, Danenberg PV.

Cancer Chemother Pharmacol. 2010 Apr;65(5):825-31. doi: 10.1007/s00280-009-1087-5. Epub 2009 Aug 22.

PMID:
19701635
18.

A three-gene signature for outcome in soft tissue sarcoma.

Hoffmann AC, Danenberg KD, Taubert H, Danenberg PV, Wuerl P.

Clin Cancer Res. 2009 Aug 15;15(16):5191-8. doi: 10.1158/1078-0432.CCR-08-2534. Epub 2009 Aug 11. Erratum in: Clin Cancer Res. 2009 Oct;15(20):6472. Hoffman, Andreas-Claudius [corrected to Hoffmann, Andreas-Claudius].

19.

Loss of heterozygosity at thymidylate synthase locus in Barrett's metaplasia, dysplasia, and carcinoma sequences.

Kuramochi H, Uchida K, Peters JH, Shimizu D, Vallbohmer D, Schneider S, Danenberg KD, Danenberg PV.

BMC Cancer. 2009 May 21;9:157. doi: 10.1186/1471-2407-9-157.

20.

Messenger RNA expression of COX-2 and angiogenic factors in primary colorectal cancer and corresponding liver metastasis.

Kobayashi H, Sugihara K, Uetake H, Higuchi T, Yasuno M, Enomoto M, Iida S, Lenz HJ, Danenberg KD, Danenberg PV.

Int J Oncol. 2009 Apr;34(4):1147-53.

PMID:
19287974
22.

Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue.

Hewitt SM, Lewis FA, Cao Y, Conrad RC, Cronin M, Danenberg KD, Goralski TJ, Langmore JP, Raja RG, Williams PM, Palma JF, Warrington JA.

Arch Pathol Lab Med. 2008 Dec;132(12):1929-35. doi: 10.1043/1543-2165-132.12.1929. Review.

PMID:
19061293
23.
24.

Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.

Kobayashi H, Sugihara K, Uetake H, Higuchi T, Yasuno M, Enomoto M, Iida S, Azuma M, Mori R, Omori A, Lenz HJ, Danenberg KD, Danenberg PV.

Int J Oncol. 2008 Dec;33(6):1257-62.

PMID:
19020759
25.

Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells.

Mori R, Xiong S, Wang Q, Tarabolous C, Shimada H, Panteris E, Danenberg KD, Danenberg PV, Pinski JK.

Prostate. 2009 Jan 1;69(1):12-23. doi: 10.1002/pros.20851.

PMID:
18814146
26.

High expression of heparanase is significantly associated with dedifferentiation and lymph node metastasis in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA and via HIF1a to HB-EGF and bFGF.

Hoffmann AC, Mori R, Vallbohmer D, Brabender J, Drebber U, Baldus SE, Klein E, Azuma M, Metzger R, Hoffmann C, Hoelscher AH, Danenberg KD, Prenzel KL, Danenberg PV.

J Gastrointest Surg. 2008 Oct;12(10):1674-81; discussion 1681-2. doi: 10.1007/s11605-008-0628-2. Epub 2008 Aug 13.

PMID:
18704599
27.

Both beta-actin and GAPDH are useful reference genes for normalization of quantitative RT-PCR in human FFPE tissue samples of prostate cancer.

Mori R, Wang Q, Danenberg KD, Pinski JK, Danenberg PV.

Prostate. 2008 Oct 1;68(14):1555-60. doi: 10.1002/pros.20815.

PMID:
18651557
28.

High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF.

Hoffmann AC, Mori R, Vallbohmer D, Brabender J, Klein E, Drebber U, Baldus SE, Cooc J, Azuma M, Metzger R, Hoelscher AH, Danenberg KD, Prenzel KL, Danenberg PV.

Neoplasia. 2008 Jul;10(7):674-9.

29.

Prognostic value of the androgen receptor and its coactivators in patients with D1 prostate cancer.

Mori R, Wang Q, Quek ML, Tarabolous C, Cheung E, Ye W, Groshen S, Hawes D, Togo S, Shimada H, Danenberg KD, Danenberg PV, Pinski JK.

Anticancer Res. 2008 Jan-Feb;28(1B):425-30.

30.

High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1.

Kuramochi H, Hayashi K, Uchida K, Nakajima G, Hatori T, Danenberg KD, Danenberg PV, Yamamoto M.

Cancer Chemother Pharmacol. 2008 Dec;63(1):85-9. doi: 10.1007/s00280-008-0714-x. Epub 2008 Feb 29.

PMID:
18309485
31.

Messenger RNA expression of vascular endothelial growth factor and its receptors in primary colorectal cancer and corresponding liver metastasis.

Kobayashi H, Sugihara K, Uetake H, Higuchi T, Yasuno M, Enomoto M, Kuramochi H, Lenz HJ, Danenberg KD, Danenberg PV.

Ann Surg Oncol. 2008 Apr;15(4):1232-8. doi: 10.1245/s10434-008-9811-7. Epub 2008 Feb 1.

PMID:
18239970
32.

Thymidylate synthase polymorphisms and mRNA expression are independent chemotherapy predictive markers in esophageal adenocarcinoma patients.

Kuramochi H, Tanaka K, Oh D, Lehman BJ, Dunst CM, Yang DY, De Meester SR, Hagen JA, Danenberg KD, De Meester TR, Danenberg PV.

Int J Oncol. 2008 Jan;32(1):201-8.

PMID:
18097560
33.

Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients.

Azuma M, Shi M, Danenberg KD, Gardner H, Barrett C, Jacques CJ, Sherod A, Iqbal S, El-Khoueiry A, Yang D, Zhang W, Danenberg PV, Lenz HJ.

Pharmacogenomics. 2007 Dec;8(12):1705-13.

PMID:
18086000
34.

Towards the molecular characterization of disease: comparison of molecular and histological analysis of esophageal epithelia.

Vallböhmer D, Marjoram P, Kuramochi H, Shimizu D, Jung H, DeMeester SR, Oh D, Chandrasoma PT, Danenberg KD, DeMeester TR, Danenberg PV, Peters JH.

J Gastrointest Surg. 2007 Sep;11(9):1095-104.

PMID:
17623264
35.

DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.

Vallböhmer D, Yang DY, Kuramochi H, Shimizu D, Danenberg KD, Lindebjerg J, Nielsen JN, Jakobsen A, Danenberg PV.

Int J Oncol. 2007 Aug;31(2):413-8.

PMID:
17611699
36.

Reduction of interleukin 8 gene expression in reflux esophagitis and Barrett's esophagus with antireflux surgery.

Oh DS, DeMeester SR, Vallbohmer D, Mori R, Kuramochi H, Hagen JA, Lipham J, Danenberg KD, Danenberg PV, Chandrasoma P, DeMeester TR.

Arch Surg. 2007 Jun;142(6):554-9; discussion 559-60.

PMID:
17576892
37.

Plasma DNA as a molecular marker for completeness of resection and recurrent disease in patients with esophageal cancer.

Banki F, Mason RJ, Oh D, Hagen JA, DeMeester SR, Lipham JC, Tanaka K, Danenberg KD, Yacoub WN, Danenberg PV, DeMeester TR.

Arch Surg. 2007 Jun;142(6):533-8; discussion 538-9.

PMID:
17576889
38.

Predictive value of MSH2 gene expression in colorectal cancer treated with capecitabine.

Jensen LH, Danenberg KD, Danenberg PV, Jakobsen A.

Clin Colorectal Cancer. 2007 Mar;6(6):433-5.

PMID:
17531106
39.

Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer.

Yang D, Schneider S, Azuma M, Iqbal S, El-Khoueiry A, Groshen S, Agafitei D, Danenberg KD, Danenberg PV, Ladner RD, Lenz HJ.

Clin Colorectal Cancer. 2006 Nov;6(4):305-11.

PMID:
17241515
40.

Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer.

Azuma M, Danenberg KD, Iqbal S, El-Khoueiry A, Zhang W, Yang D, Koizumi W, Saigenji K, Danenberg PV, Lenz HJ.

Clin Colorectal Cancer. 2006 Sep;6(3):214-8.

PMID:
17026791
41.

ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.

Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, Cambieri A, Selvaggi G, Saviozzi S, Calogero R, Papotti M, Scagliotti GV.

Ann Oncol. 2006 Dec;17(12):1818-25. Epub 2006 Sep 15.

PMID:
16980606
42.

Molecular determinants of irinotecan efficacy.

Vallböhmer D, Iqbal S, Yang DY, Rhodes KE, Zhang W, Gordon M, Fazzone W, Schultheis AM, Sherrod AE, Danenberg KD, Lenz HJ.

Int J Cancer. 2006 Nov 15;119(10):2435-42.

43.

DNA methyltransferases messenger RNA expression and aberrant methylation of CpG islands in non-small-cell lung cancer: association and prognostic value.

Vallböhmer D, Brabender J, Yang D, Schneider PM, Metzger R, Danenberg KD, Hölscher AH, Danenberg PV.

Clin Lung Cancer. 2006 Jul;8(1):39-44.

PMID:
16870044
44.

Cdx-2 expression in squamous and metaplastic columnar epithelia of the esophagus.

Vallböhmer D, DeMeester SR, Peters JH, Oh DS, Kuramochi H, Shimizu D, Hagen JA, Danenberg KD, Danenberg PV, DeMeester TR, Chandrasoma PT.

Dis Esophagus. 2006;19(4):260-6.

PMID:
16866857
45.

Antireflux surgery normalizes cyclooxygenase-2 expression in squamous epithelium of the distal esophagus.

Vallböhmer D, DeMeester SR, Oh DS, Banki F, Kuramochi H, Shimizu D, Hagen JA, Danenberg KD, Danenberg PV, Chandrasoma PT, Peters JH, DeMeester TR.

Am J Gastroenterol. 2006 Jul;101(7):1458-66.

PMID:
16863546
46.

Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation.

Schneider S, Park DJ, Yang D, El-Khoueiry A, Sherrod A, Groshen S, Streeter O, Iqbal S, Danenberg KD, Lenz HJ.

Pharmacogenet Genomics. 2006 Aug;16(8):555-63.

PMID:
16847424
47.

Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer.

Dziadziuszko R, Witta SE, Cappuzzo F, Park S, Tanaka K, Danenberg PV, Barón AE, Crino L, Franklin WA, Bunn PA Jr, Varella-Garcia M, Danenberg KD, Hirsch FR.

Clin Cancer Res. 2006 May 15;12(10):3078-84.

48.

Molecular determinants in targeted therapy for esophageal adenocarcinoma.

Vallböhmer D, Peters JH, Kuramochi H, Oh D, Yang D, Shimizu D, DeMeester SR, Hagen JA, Chandrasoma PT, Danenberg KD, Danenberg PV, DeMeester TR.

Arch Surg. 2006 May;141(5):476-81; discussion 481-2.

PMID:
16702519
49.

5-fluorouracil-related gene expression levels in primary colorectal cancer and corresponding liver metastasis.

Kuramochi H, Hayashi K, Uchida K, Miyakura S, Shimizu D, Vallbohmer D, Park S, Danenberg KD, Takasaki K, Danenberg PV.

Int J Cancer. 2006 Aug 1;119(3):522-6.

50.

Increasing cyclooxygenase-2 (cox-2) gene expression in the progression of Barrett's esophagus to adenocarcinoma correlates with that of Bcl-2.

Shimizu D, Vallböhmer D, Kuramochi H, Uchida K, Schneider S, Chandrasoma PT, Shimada H, DeMeester TR, Danenberg KD, Peters JH, DeMeester SR, Danenberg PV.

Int J Cancer. 2006 Aug 15;119(4):765-70.

Supplemental Content

Loading ...
Support Center